[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"silodosin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:silodosin":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100592137","clinical-outcomes-and-ejaculatory-function-in-bpo-patients-treated-with-silodosin-100592137",false,"NCT06989515","Clinical Outcomes and Ejaculatory Function in BPO Patients Treated With Silodosin","Does Anejaculation Reflect Better Clinical Outcomes in BPO Patients Receiving Silodosin?","Inclusion Criteria:\n\n* Male patients aged 40 years or older\n* Diagnosed with lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO)\n* Initiating silodosin 8 mg\u002Fday therapy for the first time\n* Able to complete IPSS and IIEF-5 questionnaires\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* History of prior treatment with silodosin or other α-blockers in the last 3 months\n* Known neurogenic bladder or history of neurological disease affecting voiding\n* History of prostate surgery or pelvic radiation\n* Diagnosed prostate or bladder malignancy\n* Use of medications affecting sexual function (e.g., PDE5 inhibitors) within the last month\n* Severe cardiovascular, hepatic, or renal comorbidities\n* Cognitive impairment preventing informed consent or questionnaire completion","MALE","40 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This observational study aims to evaluate the relationship between silodosin-induced anejaculation and clinical outcomes in male patients with benign prostatic obstruction (BPO). Silodosin is a commonly used alpha-blocker for lower urinary tract symptoms (LUTS). However, it may cause ejaculatory dysfunction, particularly anejaculation. In this study, patients receiving silodosin for the first time will be grouped based on whether they experience anejaculation or not. Treatment response will be assessed using urinary flow rate, post-void residual urine, and International Prostate Symptom Score (IPSS). Sexual function will be evaluated using the International Index of Erectile Function-5 (IIEF-5) before and after treatment. The study aims to explore whether the presence of anejaculation is associated with improved symptom relief or differences in sexual health.",[24,25,26,27,28],"Benign Prostate Obstruction (BPO)","Lower Urinary Tract Symptom","Ejaculatory Dysfunction","Anejaculation","Silodosin",[28,26,30,31,32],"Benign Prostatic Obstruction","Lower Urinary Tract Symptoms","Alpha-blocker Side Effects","NOT_YET_RECRUITING","2025-06-04",{"date":36,"type":37},"2025-06-05","ACTUAL",{"date":39,"type":20},"2025-06-15",{"date":41,"type":20},"2026-06-12",{"name":43,"class":44},"Marmara University","OTHER"]